ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Jan 16, 2023 18:56 JST
Source:
Eisai
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
TOKYO and CAMBRIDGE, Mass., Jan 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril(1) antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia (collectively known as early AD) with confirmed presence of amyloid pathology in the brain to the Pharmaceuticals and Medical Devices Agency (PMDA).
This application is based on the results of the Phase III Clarity AD study and Phase IIb clinical study (Study 201), which demonstrated the lecanemab treatment showed a reduction of clinical decline in early AD. Prior to submitting this application, Eisai utilized the prior assessment consultation system of PMDA, with the aim of shortening the review period for lecanemab.
In the Clarity AD study, lecanemab treatment resulted in highly statistically significant results, reducing clinical decline on the global cognitive and functional scale as the primary endpoint (CDR-SB(2): Clinical Dementia Rating-Sum of Boxes) as early as six months, and over time across all time points. All key secondary endpoints also showed highly statistically significant results. Especially, treatment with lecanemab showed a statistically significant reduction in amyloid plaque burden at all timepoints starting at 3 months in the amyloid PET study and statistically significantly slowed decline of activities of daily living on ADCS MCI-ADL(3). The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.
In November 2022, the results of Clarity AD study were presented at the 15th Clinical Trials on Alzheimer's Disease (CTAD) conference and simultaneously published in the peer-reviewed medical journal the New England Journal of Medicine(New Window).
In the U.S., lecanemab was granted accelerated approval as a treatment for AD by the U.S. Food and Drug Administration (FDA) on January 6, 2023. On the same day, Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway. In Europe, Eisai submitted marketing authorization application (MAA) to the European Medicines Agency (EMA) on January 9, 2023. In China, Eisai initiated submission of data for BLA to the National Medical Products Administration (NMPA) of China in December 2022.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully gain health authority approval.
For more information, visit www.eisai.com/news/2023/news202307.html.
MEDIA CONTACT:
Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120
Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
Libby_Holman@eisai.com
INVESTOR CONTACT:
Eisai Co., Ltd.
Investor Relations Department
TEL: +81-(0)03-3817-5122
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MHI Thermal Systems Develops Electric-Driven Transport Refrigeration Units with Heat-Pump Heating System for Domestic EV Trucks
Mar 30, 2023 16:27 JST
Mitsubishi Power Supporting Efficient Utilization of Hydrogen in the Petroleum Refining Process
Mar 30, 2023 16:00 JST
Hitachi Energy to support the transmission of increasing volumes of sustainable electricity to California
Mar 30, 2023 15:00 JST
Toyota: Sales, Production, and Export Results for February 2023
Mar 30, 2023 13:36 JST
Hitachi Vantara and Golden Grove Nursery Harness Data-Driven Analytics for More Sustainable Water Management
Mar 29, 2023 16:17 JST
Whitbread and Fujitsu sign a multimillion technology service partnership deal to bolster IT services in Premier Inn and restaurant brands
Mar 29, 2023 16:16 JST
JCB and Joint Stock Commercial Bank for Foreign Trade of Vietnam launch VCB JCB Platinum Credit Card in Vietnam
Mar 29, 2023 16:00 JST
Mazda Joins Research Association of Biomass Innovation for Next Generation Automobile Fuels
Mar 29, 2023 11:44 JST
NEC Technology Successfully Predicts High Risk Areas for Presence of Landmines
Mar 29, 2023 10:09 JST
Mitsubishi Shipbuilding Holds Launch Ceremony in Shimonoseki for Demonstration Test Ship for Liquefied CO2 Transport
Mar 28, 2023 14:07 JST
MHI Awarded 7-Year Long Term Service Agreement for 400 MW Combined Cycle Power Plant in Bangladesh
Mar 28, 2023 13:55 JST
Toyota to Establish a New Company to Promote the Fuji Motorsports Forest Project
Mar 28, 2023 13:42 JST
Asahi Kasei and NEC establish analysis platform utilizing secure computation technology for secure data collaboration between companies
Mar 28, 2023 11:14 JST
Fujitsu launches new cloud-based platform for healthcare sector in Japan, promoting personalized healthcare and drug development
Mar 28, 2023 10:17 JST
DENSO Wins Silver Medal at the 10th International Abilympics
Mar 27, 2023 19:37 JST
Hitachi Continuously Selected as CDP Supplier Engagement Leader
Mar 27, 2023 18:52 JST
Educational Manga Prepared as Teaching Tool for school child: "The Secrets of SDGs - Affordable and Clean Energy"
Mar 27, 2023 15:21 JST
Mazda: Conclusion of offsite corporate power purchase agreement (PPA) on solar power generation
Mar 27, 2023 14:52 JST
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Mar 24, 2023 13:22 JST
Mitsubishi Corporation: PoC Launched in Portland, Oregon to Develop Smart Multifamily Apartment
Mar 24, 2023 11:02 JST
More Latest Release >>
Related Release
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
3/24/2023 1:22:00 PM JST
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
3/23/2023 1:30:00 PM JST
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal
3/20/2023 11:18:00 AM JST
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease
3/14/2023 11:09:00 AM JST
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award
3/10/2023 3:04:00 PM JST
Eisai Certified as a 2023 Health and Productivity Management Outstanding
3/9/2023 9:07:00 AM JST
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
3/6/2023 10:58:00 AM JST
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan
3/2/2023 10:45:00 AM JST
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
2/28/2023 3:28:00 PM JST
Dissolution of Bracco-Eisai Joint Venture
2/21/2023 2:02:00 PM JST
More Press release >>